



September 20, 2010 10:00 AM Eastern Daylight Time

ABL Announces the Strengthening of Its Patent Estate: Notice of Allowance in Canada, Issuance of a Patent in India, and Issuance of Reexamination Certificates in the United States after Several Patent Reexaminations

LUXEMBOURG--([BUSINESS WIRE](#))--Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. [6,081,786](#) and [6,188,988](#) to Barry et al.

In the United States, the '786 and '988 patents each have been challenged by four separate patent reexamination requests, which have all been denied or had prosecution closed. In each case, the U.S. Patent and Trademark Office affirmed the patentability of Claims 1-66 of each patent without amendment, and reexamination certificates have been issued or are pending for each patent.

"We are very pleased with this positive news, confirming the innovative value of our patent estate, and reinforcing the patentability of the '786 and '988 patents," said Dr. Chalom Sayada, CEO of ABL. "This news will allow us to continue to develop our commercial activities in the U.S., Canada, and India with our proprietary technology, TherapyEdge™ and ViroScore™. They further reinforce our decision to support all research and not-for-profit activities, while providing potential patent licensing opportunities for those with commercial products in the personalized healthcare business."

ABL has actively engaged with academics and researchers to teach them more about ABL's patents and its willingness to collaborate with the scientific and nonprofit community by providing unrestricted access to ABL's patents, both in the U.S. and in developing countries.

"This further solidifies the domestic and international intellectual property protection strategy we have implemented for the past several years," continued Dr Sayada. "The issuance of these patents and the affirmation of the U.S. patents will be very important to further expanding our worldwide patent protection and business development for our TherapyEdge™ platform with strategic corporate and industrial partners."

About ABL S.A.: Advanced Biological Laboratories (ABL) S.A. is an information technology company dedicated to develop healthcare products and services to enable its customers deliver high-quality and optimal personalized healthcare by streamlining processes and improving the quality and safety of patient care. Over the last 10 years, ABL has developed its proprietary TherapyEdge™ Electronic Medical Record System, to manage all conditions, medications, and laboratory tests, with integrated modules to enable personalized disease management using clinical, biological and genetics decision support algorithms for HIV/AIDS, Viral Hepatitis and Tuberculosis. The TherapyEdge™ and ViroScore™ Suite platforms are fully integrated with hospital information systems (HIS) and laboratory information system (LIS) according industry standards. ABL is engaged in several research projects and international collaborations in the field of molecular diagnostics and personalized healthcare in the European Union, the USA, Africa and Asia. TherapyEdge™ and ViroScore™ Suite are covered by international intellectual property portfolio. More information available at: <http://www.therapyedge.com>

Contacts

Dr Chalom B. SAYADA, MD, PhD
CEO ABL SA
Tel: +352-2638-8921

Permalink: <http://www.businesswire.com/news/home/20100920005969/en/ABL-Announces-Strengthening-Patent-Estate-Notice-Allowance>

"The issuance of these patents and the affirmation of the U.S. patents will be very important to further expanding our worldwide patent protection and business development for our TherapyEdge™ platform with strategic corporate and industrial partners."
